Refining Prognostication in Advanced Mycosis Fungoides and Sézary Syndrome: The Role of the Cutaneous Lymphoma International Prognostic Index (CLIPI)

Highlight

• The Cutaneous Lymphoma International Prognostic Index (CLIPI) incorporates clinical and laboratory parameters to improve risk stratification in advanced mycosis fungoides (MF) and Sézary syndrome (SS).
• CLIPI effectively predicts progression-free survival (PFS) and the best objective response (BOR) during follow-up, surpassing the prognostic value of traditional TNMB staging.
• Higher CLIPI scores are correlated with increased risks of disease progression and death, and lower odds of favorable treatment response.
• Integrating CLIPI into routine clinical practice may optimize treatment decisions and inform clinical trial designs for MF/SS.

Study Background